HIV-1 risk and vaccine acceptability in the Ugandan military

被引:36
作者
Hom, DL
Johnson, JL
Mugyenyi, P
Byaruhanga, R
Kityo, C
Louglin, A
Svilar, GM
Vjecha, M
Mugerwa, RD
Ellner, JJ
机构
[1] UNIV HOSP CLEVELAND,CLEVELAND,OH 44106
[2] JOINT CLIN RES CTR,KAMPALA,UGANDA
[3] MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1997年 / 15卷 / 05期
关键词
HIV-1; seroincidence; seroprevalence; Africa; Uganda; anti-HIV vaccine; vaccine acceptability;
D O I
10.1097/00042560-199708150-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Between July and October 1993, 570 19- to 22-year-old volunteers were screened for HIV-1, with a resulting seroprevalence rate of 18.3% (95% CI: 14.0%, 22.6%). A cohort of 249 HIV-1-noninfected military recruits in the Ugandan Peoples'0 Defense Forces was followed prospectively for up to 18 months to document rates of HIV-1 seroprevalence, seroconversion, and knowledge and attitudes related to vaccine acceptability. The HIV-1 seroincidence rate was 3.56 per 100 person-years (95% CI: 1.49, 5.62) over 309 person-years of observation, At the 3- and 12-month visits, subjects were interviewed on issues of acceptance and knowledge about vaccines, including anti-HIV vaccines in particular. More than 90% believe that HIV vaccines will not cause HIV infection, and if offered, 88% report that they would take the vaccine if they were not already infected. Nonvaccine prevention methods were considered less reliable; monogamy and condom use were considered effective by only 33.5% and 69.3% of the cohort respectively. After completing the vaccine acceptability questionnaire at the 12-month visit, subjects were offered an approved polyvalent meningococcal vaccine as an indicator of general vaccine acceptance. All subjects reported receiving at least one previous vaccination, and 95% willingly accepted the meningococcal vaccination. The Ugandan military is a stable population at substantial risk for HIV-1 infection and may be a suitable population for vaccine efficacy trials.
引用
收藏
页码:375 / 380
页数:6
相关论文
共 28 条
[1]  
ASIIMWEOKIROR G, 1995, 9 INT C AIDS STD AFR
[2]  
BAGENDA D, 1995, 9 INT C AIDS STD AFR
[3]  
CARR JK, 1994, J ACQ IMMUN DEF SYND, V7, P1270
[4]   WILLINGNESS TO PARTICIPATE IN AIDS VACCINE TRIALS AMONG HIGH-RISK POPULATIONS IN NORTHERN THAILAND [J].
CELENTANO, DD ;
BEYRER, C ;
NATPRATAN, C ;
EIUMTRAKUL, S ;
SUSSMAN, L ;
RENZULLO, PO ;
KHAMBOONRUANG, C ;
NELSON, KE .
AIDS, 1995, 9 (09) :1079-1083
[5]  
Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1
[6]   MEASURING THE IMPACT OF HIV/AIDS IN AFRICA [J].
DECOCK, KM .
AIDS, 1994, 8 (01) :127-128
[7]   THE PUBLIC-HEALTH IMPLICATIONS OF AIDS RESEARCH IN AFRICA [J].
DECOCK, KM ;
EKPINI, E ;
GNAORE, E ;
KADIO, A ;
GAYLE, HD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06) :481-486
[8]  
GRANT RM, 1992, 8 INT C AIDS AMST NE
[9]  
HOFF R, 1995, INFECT AGENT DIS, V4, P95
[10]  
HOM DL, 1993, PEDIATR AIDS HIV INF, V4, P74